{"id":32825,"date":"2025-02-10T16:17:01","date_gmt":"2025-02-10T13:17:01","guid":{"rendered":"https:\/\/massivebio.com\/?p=32825"},"modified":"2025-05-26T12:58:28","modified_gmt":"2025-05-26T09:58:28","slug":"open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte","status":"publish","type":"post","link":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/","title":{"rendered":"An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community"},"content":{"rendered":"<section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><p>February 2025<\/p>\n<p>Dear Colleagues,<\/p>\n<p>In light of the recent developments regarding the <a href=\"https:\/\/www.linkedin.com\/company\/national-institutes-of-health\">The National Institutes of Health<\/a>\u2019s (NIH) abrupt reduction of indirect cost rates\u2014from historical levels approaching <a href=\"https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-25-068.html\">50\u201360% down to 15%<\/a>\u2014our entire research ecosystem faces challenges unseen in recent memory. This funding shift, while intended to tighten budgets and increase efficiency, will undoubtedly affect clinical trials, accelerate staff reductions, and risk delaying life-saving breakthroughs. We at <a href=\"https:\/\/www.linkedin.com\/company\/massivebio\">Massive Bio<\/a> recognize the gravity of these concerns. Today, we wish to affirm our commitment to supporting the cancer community\u2014patients, investigators, research centers, federal partners, and sponsors\u2014through collaborative, technology-driven solutions that strengthen our collective capacity to advance cancer research.<\/p>\n<h2 style=\"font-size: 24px;\">Our Mission &amp; Background<\/h2>\n<p>Massive Bio was founded on the principle that every patient deserves timely, real-time access to clinical trials. From the beginning, our vision was catalyzed by an SBIR NIH\/NCI grant, <em>\u201cCancer Clinical Trials Recruitment and Retention Tools for Participant Engagement,\u201d<\/em> which enabled us to build and refine a patient-centric, digitally enabled <a href=\"https:\/\/massivebio.com\/\">Deep Learning Clinical Trial Matching System (DLCTMS, aka SYNERGY-AI)<\/a>. This system delivers near-real-time trial matching, breaking down traditional enrollment barriers. By deploying data-driven technology, we have helped connect thousands of patients to trials that may offer them renewed hope, while simultaneously empowering investigators to complete studies on time and within budget.<\/p>\n<p>With indirect cost rates now capped at 15%, many research institutions\u2014particularly <a href=\"https:\/\/www.linkedin.com\/company\/nationalcancerinstitute\">National Cancer Institute (NCI)<\/a> designated cancer centers\u2014are bracing for reduced support staff, deferred facility maintenance, and tighter budgets for critical programs that facilitate trial accrual. These cutbacks threaten to delay study activation, halt recruitment, and slow the approvals of new <a href=\"https:\/\/www.linkedin.com\/company\/fda\">FDA<\/a> therapies. Equally concerning is the impact on underserved communities, whose access to groundbreaking trials may be curtailed by centers forced to scale back due to financial strain.<\/p>\n<h2 style=\"font-size: 24px;\"><strong>Our Commitment to Collaboration and Solutions<\/strong><\/h2>\n<p>We believe the path forward lies in unified, innovative partnerships. Although the current funding landscape is uncertain, Massive Bio stands ready to collaborate with NCI-designated centers, community research sites, government agencies, and the broader oncology community by:<\/p>\n<ul>\n<li>\n<h3 style=\"font-size: 18px;\"><strong>Leveraging Scalable Technology:<\/strong><\/h3>\n<p>Our SYNERGY-AI platform fast-tracks patient pre-screening and enrollment, reducing administrative burdens and improving operational efficiencies for institutions already stretched thin. By automating trial-matching and streamlining workflows, we enable research centers to do more with fewer resources.<\/li>\n<li>\n<h3 style=\"font-size: 18px;\"><strong>Expanding Clinical Trial Access:<\/strong><\/h3>\n<p>Massive Bio\u2019s core objective is to ensure that no patient is left behind due to geography, socioeconomic status, or lack of awareness. Our platform extends reach into communities, bridging gaps in clinical trial availability and connecting patients to potentially life-saving options.<\/li>\n<li>\n<h3 style=\"font-size: 18px;\"><strong>Supporting Financial Sustainability:<\/strong><\/h3>\n<p>We recognize that revenue generation is essential to keep research programs viable. By enhancing enrollment rates, we help secure clinical trials funding while reducing costly delays. Stable and predictable accrual fosters more robust partnerships with sponsors\u2014across pharma, biotech, and government agencies\u2014strengthening the financial backbone of cancer centers.<\/li>\n<li>\n<h3 style=\"font-size: 18px;\"><strong>Driving Collaborative Models at Scale:<\/strong><\/h3>\n<p>Our recent <a href=\"https:\/\/www.precisioncancerconsortium.com\/revolutionizing-cancer-trial-matching-pcc-and-massive-bios-ai-driven-multi-sponsor-study-delivers-promising-results\/\">PCC ASCO abstract<\/a> underscores that multi-stakeholder collaboration (including pharma sponsors, government entities, technology vendors, and patient advocates) can be both practical and mutually beneficial. By aligning incentives and sharing data responsibly, we accelerate discovery without overburdening any single participant.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px;\"><strong>Working Hand in Hand with Government Agencies<\/strong><\/h2>\n<p>Our beginnings were made possible through an NCI SBIR grant, and we remain dedicated to fostering public-private partnerships. Amid tightening budgets, we believe new, digitally enabled efficiencies must be part of the solution. Whether implementing electronic pre-screening hubs or refining remote consent processes, government collaboration is pivotal to ensure our national research priorities remain intact.<\/p>\n<h2 style=\"font-size: 24px;\"><strong>A Call to Action<\/strong><\/h2>\n<p>In these uncertain times, we urge all research institutions\u2014particularly those facing the harshest budget contractions\u2014to consider how novel digital platforms can maintain momentum for current trials and lay the foundation for future breakthroughs. By partnering with Massive Bio, institutions can:<\/p>\n<ul>\n<li>Increase trial awareness and enrollment, safeguarding your research programs against resource shortfalls.<\/li>\n<li>Offer innovative, patient-centric care that meets modern standards of accessibility and equity.<\/li>\n<li>Achieve cost savings through optimized trial management and more efficient workflows.<\/li>\n<\/ul>\n<p>Above all, our patients\u2014especially those with few other therapeutic options\u2014are counting on us to adapt, collaborate, and innovate. Despite financial headwinds, we must remain steadfast in our shared mission to reduce the global burden of cancer.<\/p>\n<p>At Massive Bio, we believe that hope and innovation thrive best in environments where collaboration transcends economic barriers. Now more than ever, it is critical to forge partnerships and harness technology to keep cancer research moving forward.<\/p>\n<p>We stand ready to work alongside you\u2014cancer centers, investigators, federal agencies, sponsors, and community clinics\u2014to ensure that clinical trials remain a beacon of possibility. Together, we will turn these funding challenges into opportunities for evolution, improving outcomes for patients everywhere and continuing to advance the frontiers of science in the United States and the world.<\/p>\n<p>If you wish to learn more about our platforms, explore partnerships, or discuss how we can support your center\u2019s clinical trial programs, please reach out to us directly. We welcome your ideas and look forward to forging a path of resilience and innovation with you.<\/p>\n<p>Sincerely,<\/p>\n<p><strong>Arturo Loaiza-Bonilla, MD, MSEd, FACP<\/strong><\/p>\n<p>Co-Founder &amp; Chief Medical Officer<\/p>\n<p><strong>on behalf of Massive Bio co-founders <\/strong><a href=\"https:\/\/www.linkedin.com\/in\/selinkurnaz\">Selin Kurnaz, PhD<\/a><strong>, <\/strong><a href=\"https:\/\/www.linkedin.com\/in\/cagatayculcuoglu?trk=article-ssr-frontend-pulse_little-mention\">\u00c7a\u011fatay M. \u00c7ulcuo\u011flu <\/a><strong>and our team<\/strong><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"February 2025 Dear Colleagues, In light of the recent developments regarding the The National Institutes of Health\u2019s (NIH) abrupt reduction of indirect cost rates\u2014from historical levels approaching 50\u201360% down to 15%\u2014our entire research ecosystem faces challenges unseen in recent memory. This funding shift, while intended to tighten budgets and increase efficiency, will undoubtedly affect clinical...","protected":false},"author":11,"featured_media":32826,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-32825","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community<\/title>\n<meta name=\"description\" content=\"Our commitment to collaboration and solutions. We believe the path forward lies in unified, innovative partnerships.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community %\" \/>\n<meta property=\"og:description\" content=\"Our commitment to collaboration and solutions. We believe the path forward lies in unified, innovative partnerships.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/\" \/>\n<meta property=\"og:site_name\" content=\"Massive Bio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-10T13:17:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-26T09:58:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/Arturo-OpenLetterVisual.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"769\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sinan Gul\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:site\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sinan Gul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community","description":"Our commitment to collaboration and solutions. We believe the path forward lies in unified, innovative partnerships.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/","og_locale":"en_US","og_type":"article","og_title":"An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community %","og_description":"Our commitment to collaboration and solutions. We believe the path forward lies in unified, innovative partnerships.","og_url":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/","og_site_name":"Massive Bio","article_publisher":"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","article_published_time":"2025-02-10T13:17:01+00:00","article_modified_time":"2025-05-26T09:58:28+00:00","og_image":[{"width":769,"height":576,"url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/Arturo-OpenLetterVisual.webp","type":"image\/webp"}],"author":"Sinan Gul","twitter_card":"summary_large_image","twitter_creator":"@MassiveBio","twitter_site":"@MassiveBio","twitter_misc":{"Written by":"Sinan Gul","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/#article","isPartOf":{"@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/"},"author":{"name":"Sinan Gul","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6"},"headline":"An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community","datePublished":"2025-02-10T13:17:01+00:00","dateModified":"2025-05-26T09:58:28+00:00","mainEntityOfPage":{"@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/"},"wordCount":896,"publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"image":{"@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/Arturo-OpenLetterVisual.webp","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/","url":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/","name":"An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community","isPartOf":{"@id":"https:\/\/massivebio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/#primaryimage"},"image":{"@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/Arturo-OpenLetterVisual.webp","datePublished":"2025-02-10T13:17:01+00:00","dateModified":"2025-05-26T09:58:28+00:00","description":"Our commitment to collaboration and solutions. We believe the path forward lies in unified, innovative partnerships.","breadcrumb":{"@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/#primaryimage","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/Arturo-OpenLetterVisual.webp","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/Arturo-OpenLetterVisual.webp","width":769,"height":576,"caption":"Arturo OpenLetterVisual"},{"@type":"BreadcrumbList","@id":"https:\/\/massivebio.com\/open-letter-cancer-centers-research-institutions-loaiza-bonilla-md-qvnte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/massivebio.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/massivebio.com\/resources\/news-en\/"},{"@type":"ListItem","position":3,"name":"An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community"}]},{"@type":"WebSite","@id":"https:\/\/massivebio.com\/#website","url":"https:\/\/massivebio.com\/","name":"Cancer Analysis and Clinical Trial Matching","description":"Best Oncology Advisory Services By Cancer Treatment Care Specialists &amp; Tumor Board Experts in America","publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/massivebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/massivebio.com\/#organization","name":"Massive Bio","url":"https:\/\/massivebio.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","width":"1024","height":"1024","caption":"Massive Bio"},"image":{"@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","https:\/\/x.com\/MassiveBio","https:\/\/instagram.com\/massive_bio\/","https:\/\/tiktok.com\/@massivebio","https:\/\/youtube.com\/massivebio"],"email":"support@massivebio.com","legalName":"Massive Bio"},{"@type":"Person","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6","name":"Sinan Gul"}]}},"_links":{"self":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/32825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/comments?post=32825"}],"version-history":[{"count":4,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/32825\/revisions"}],"predecessor-version":[{"id":35536,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/32825\/revisions\/35536"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media\/32826"}],"wp:attachment":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media?parent=32825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/categories?post=32825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/tags?post=32825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}